Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4115-4122

  Held, Gerhard ^a   Zeynalova, Samira ^c   Murawski, Niels ^a   Ziepert, Marita ^c   Kempf, Barbara ^d   Viardot, Andreas ^e   Dreyling, Martin ^f   Hallek, Michael ^g   Witzens Harig, Mathias ^h   Fleckenstein, Jochen ^a   Rübe, Christian ^a   Zwick, Carsten ⁱ   Glass, Bertram ^b   Schmitz, Norbert ^b   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Klinikum Landshut   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; DIFFUSE LARGE B CELL LYMPHOMA; EVENT FREE SURVIVAL; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION; ADOLESCENT; BONE TUMOR; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; MALE; METASTASIS; MIDDLE AGED; MORTALITY; BONE NEOPLASMS; LYMPHOMA, B-CELL; SECONDARY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84891706890     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.0467     Document Type: Article

References (36)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
2. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
3. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20- B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
4. Mikhaeel NG: Primary bone lymphoma. Clin Oncol (R Coll Radiol) 24:366-370, 2012
5. de Leval L, Braaten KM, Ancukiewicz M, et al: Diffuse large B-cell lymphoma of bone: An analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 27:1269-1277, 2003
6. Heyning FH, Hogendoorn PC, Kramer MH, et al: Primary lymphoma of bone: Extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. J Clin Pathol 62:820-824, 2009
7. Ostrowski ML, Unni KK, Banks PM, et al: Malignant lymphoma of bone. Cancer 58:2646-2655, 1986
8. Mulligan ME, McRae GA, Murphey MD: Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 173:1691-1697, 1999
9. Pfreundschuh M, Trümper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004
10. Pfreundschuh M, Trümper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004
11. Trümper L, Zwick C, Ziepert M, et al: Doseescalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol 19:538-544, 2008
12. Pfreundschuh M, Zwick C, Zeynalova S, et al: Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 19:545-552, 2008
13. Glass B, Kloess M, Bentz M, et al: Doseescalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non- Hodgkin lymphoma. Blood 107:3058-3064, 2006
14. Schmitz N, Kloess M, Reiser M, et al: Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer 106: 136-145, 2006
15. Zwick C, Hartmann F, Zeynalova S, et al: Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22:1872-1877, 2011
16. Schmitz N, Nickelsen M, Ziepert M, et al: Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13:1250-1259, 2012
17. López-Guillermo A, Colomo L, Jiménez M, et al: Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 23:2797-2804, 2005
18. Takahashi H, Tomita N, Yokoyama M, et al: Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 118:4166-4172, 2012
19. Ford DR, Wilson D, Sothi S, et al: Primary bone lymphoma: Treatment and outcome. Clin Oncol (R Coll Radiol) 19:50-55, 2007
20. Ramadan KM, Shenkier T, Sehn LH, et al: A clinicopathological retrospective study of 131 patients with primary bone lymphoma: A populationbased study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 18:129-135, 2007
21. Mü ller C, Murawski N, Wiesen MH, et al: The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119:3276-3284, 2012
22. Ott G, Ziepert M, Klapper W, et al: Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116:4916-4925, 2010
23. Baar J, Burkes RL, Bell R, et al: Primary non-Hodgkin's lymphoma of bone: A clinicopathologic study. Cancer 73:1194-1199, 1994
24. Barbieri E, Cammelli S, Mauro F, et al: Primary non-Hodgkin's lymphoma of the bone: Treatment and analysis of prognostic factors for Stage I and Stage II. Int J Radiat Oncol Biol Phys 59:760-764, 2004
25. Beal K, Allen L, Yahalom J: Primary bone lymphoma: Treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 106:2652-2656, 2006
26. Dubey P, Ha CS, Besa PC, et al: Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 37:1087-1093, 1997
27. Fidias P, Spiro I, Sobczak ML, et al: Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 45:1213-1218, 1999
28. Nasiri MR, Varshoee F, Mohtashami S, et al: Primary bone lymphoma: A clinicopathological retrospective study of 28 patients in a single institution. J Res Med Sci 16:814-820, 2011
29. Boston HC Jr, Dahlin DC, Ivins JC, et al: Malignant lymphoma (so-called reticulum cell sarcoma) of bone. Cancer 34:1131-1137, 1974
30. Zinzani PL, Carrillo G, Ascani S, et al: Primary bone lymphoma: Experience with 52 patients. Haematologica 88:280-285, 2003
31. Alencar A, Pitcher D, Byrne G, et al: Primary bone lymphoma: The University of Miami experience. Leuk Lymphoma 51:39-49, 2010
32. Pellegrini C, Gandolfi L, Quirini F, et al: Primary bone lymphoma: Evaluation of chemoimmunotherapy as front-line treatment in 21 patients. Clin Lymphoma Myeloma Leuk 11:321-325, 2011
33. Pfreundschuh M, Kuhnt E, Trümper L, et al: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013-1022, 2011
34. Récher C, Coiffier B, Haioun C, et al: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet 378: 1858-1867, 2011
35. Moog F, Kotzerke J, Reske SN: FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40:1407-1413, 1999
36. Ng AP, Wirth A, Seymour JF, et al: Early therapeutic response assessment by (18)FDGpositron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 48:596-600, 2007